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Pre-operative anaemia affects a third of patients undergoing cardiac surgery and is 
associated with increased mortality and morbidity. The National Institute for Health 
and Care Excellence (NICE) in the UK recommended in 2016 that perioperative 
teams should identify and treat patients with pre-operative anaemia before surgery. 
However, introducing new treatment protocols can be challenging in surgical 
pathways. The aim of this study was to assess the feasibility and effectiveness of 




We performed a multicentre, stepped, observational study using the UK Association 
of Cardiothoracic Anaesthesia Research Network. The primary feasibility outcome 
was the ability to set up an anaemia and intravenous iron clinic at each site. The 
primary efficacy outcome was change in haemoglobin (Hb) concentration between 
intervention and operation. Secondary outcomes included blood transfusion and 
hospital stay. Patients with anaemia were compared to those without anaemia and 




Seven out of eleven NHS hospitals successfully set up iron clinics over two years 
and 228 patients were recruited into this study; 92 were not anaemic, 72 anaemic 
but not treated and 64 who were anaemic received intravenous iron pre-operatively. 
Patients with anaemia who received intravenous iron were at higher surgical risk, 
were more likely to have a known previous history of iron deficiency or anaemia, had 
a higher rate of chronic kidney disease and were slightly more anaemic than the 
non-treated group. Intravenous iron was administered a median (IQR [range]) of 33 
(15 - 53 [4 - 303]) days before surgery. Primary efficacy endpoint showed pre-
operative intravenous iron increased [Hb] from baseline to pre-surgery; mean (95% 
CI) change was +8.4 (5.0 to 11.8) g/l (p<0.001). Overall, anaemic compared with non 
anaemic patients were more likely to be transfused than (49% (59/136) vs 27% 
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(22/92), p=0.001), and stayed longer in hospital (median days (IQR) 9 (7-15) vs. 8 
(6-11), p=0.014).  The number of days alive and at home was lower in the anaemic 
group (median days (IQR) 20 (14-22) vs. 21 (17-23), p= 0.033) There was no 
difference between treated and non-treated anaemic patients. No adverse events 
were reported in association with intravenous iron administration. 
 
Conclusion 
The development of an intravenous iron pathway is feasible but appears limited to 
selected high-risk cardiac patients in routine NHS practice. Whilst intravenous iron 
increased [Hb], there is a need for an appropriately powered clinical trial to assess 





In a large UK‐ wide study conducted by the Association of Cardiothoracic 
Anaesthetists (ACTA) in 2016, anaemia was found to be common before cardiac 
surgery and independently associated with worse outcomes, including length of stay 
in ICU and hospital, and mortality. Patients with anaemia had an increased risk of 
death following cardiac surgery1. Anaemia in the general population is common, with 
a global prevalence in excess of 30%2. This prevalence increases with age, affecting 
half the geriatric population across the UK3. An expanding body of evidence 
continually links pre-operative anaemia to increased surgical mortality, higher rates 
of transfusion, length of hospital stay and surgical complications4–6. This is 
particularly relevant in cardiac surgery where comorbidities are common, blood loss 
is greater and transfusion requirements higher7–9.  
Patient blood management (PBM) is a patient-centred, multidisciplinary 
approach to reducing blood transfusion and consists of a raft of preventative and 
reactive measures that highlight best practice and quality in blood transfusion. 
Introduction of PBM is associated with improved outcomes and reduction in cost.10 
The first pillar of PBM has focused on early detection and correction of anaemia. 
However, these recommendations for the timely of diagnosis of anaemia, with 
appropriate and early treatment present significant healthcare organisational 
challenges in an often busy setting before operation.11,12  
The commonest cause of anaemia is iron deficiency, whether absolute or 
functional; Folate and Vitamin B12 deficiency are less frequent.13 Treating iron 
deficiency anaemia effectively in the time available prior to most cardiac procedures 
is not possible with oral iron. Intravenous iron is an ideal alternative given newer 
preparations that can be administered rapidly and with less side-effects and a good 
safety profile.14 The use of intravenous iron is more effective in increasing 
haemoglobin than oral iron15 and has been observed to reduce transfusion in many 
surgical specialties.16 
In 2016, NICE reviewed transfusion practice and recommended the timely 
identification of anaemia before surgery and to consider alternatives to transfusion.17 
However, sequential audits on PBM practices across National Health Service (NHS) 
organisations show management of preoperative anaemia is frequently 
inadequate.18,19 Similarly, the implementation of PBM in Europe is limited, and 
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considerable variations exist in the assessment and treatment of preoperative 
anaemia.20 
Previously, with the Association of Cardiothoracic Anaesthetists (ACTA), we 
developed a network of enthusiastic and knowledgeable consultants interested to 
develop PBM in cardiac surgery 1 We wished to assess the feasibility of  the 
introduction of a pre-operative intravenous iron pathway into routine clinical practice, 
in line with NICE guidance. The aim of the CAVIAR study was to assess the 
introduction and efficacy of a pre-operative intravenous iron pathway to treat 







The UK Cardiac and Vascular Surgery Interventional Anaemia Response (CAVIAR) 
Study was a multicentre, stepped, observational pilot and feasibility study in patients 
undergoing cardiac and vascular surgery, the protocol for which has already been 
published.21 From a network developed with ACTA, we invited 11 UK cardiac 
surgical centres (from a total of 19 in the UK) who had expressed an interest in 
setting up anaemia treatment clinics to take part in this study. Educational support 
was provided by a core team of experts in PBM, intravenous iron and cardiac 
surgery. National UK Ethics Committee approval (ref 15/LO/1569, IRAS 188848) 
was granted and each centre obtained local approval to set up their anaemia 
pathway following UK NHS procedures, which included proformas, business plans 
and formulary application approval. Site visits were performed to every unit with 
advice and educational briefings, literature and protocols for anaemia management 
were shared between centres once developed. Three annual meetings were held to 
exchange feedback and support, regular newsletters were sent to all those involved. 
The study was designed as a stepped, prospective, observational platform 
comprising three groups of patients awaiting cardiac surgery: non-anaemic patients 
(control); anaemic patients of any cause who were not treated with IV Iron for any 
reason; and anaemic patients treated with intravenous iron before surgery. The trial 
design was published in advance.21 
Anaemia was defined according to the World Health Organization definition 
(Hb <130 g.L-1 in men and <120 g.L-1 in women). Inclusion criteria were any patient 
greater than 18 years of age undergoing elective cardiac surgery (coronary bypass, 
valve surgery or both). Exclusion criteria included: pregnant or lactating women; 
patients on renal dialysis; prisoners and patients who lacked the capacity or were 
unwilling to consent to the study. 
 
Recruitment 
Centres recruited patients consecutively, between April 2016 until March 2018, but 
over different time periods depending on the centre’s progress in setting up pre-
operative anaemia services and availability of study teams. All patients provided full 
written informed consent and were recruited as controls (non-anaemic) or those with 
anaemia. Those with anaemia and able to receive intravenous iron were recruited if 
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they fulfilled local criteria for diagnosis and treatment of Iron-deficiency anaemia 
(generally Ferritin <100 and TSAT <20%) and could attend pre-operative clinic at 
least 10 days before surgery. Those who were anaemic and qualified for IV iron 
treatment, but did not receive IV iron, for any reason, formed the anaemic non-
treated group. Largely, this was for logistical or geographical reasons. Following 
consent, collection of baseline data and blood samples, they were treated with a 
single dose intravenous iron infusion. This comprised either iron isomaltoside 1000 
(Monofer®, Pharmacosmos A/S) at a total dose calculated at 20mg/kg or ferric 
carboxymaltose (Ferinject®, Vifor Pharma UK), to a maximum of 1000mg, both by 
infusion over at least 15-30 minutes according to local policy.  Patients were 
observed during and for 30 minutes after infusion (non-invasive blood pressure, ECG 
and oxygen saturations). Anaemic patients who had received intravenous iron were 




he primary feasibility outcome was success in setting up an anaemia clinic in 
the NHS, and the primary efficacy outcome was the ability to increase Hb 
concentration between treatment and immediately before surgery with intravenous 
iron. Secondary outcomes were: blood transfusion (proportion of patients transfused, 
and number of units transfused, excluding patients who received a large transfusion 
defined as four or more units of red cells); intensive care unit and hospital length of 
stay; renal function; change in Hb from before treatment to after surgery and 
mortality. Patients were followed up for 30 days postoperatively and asked about re-
admission to hospital so that days-alive-and-at-home (DAH-30)22 could be 
calculated. DAH-30 is a composite measure that combines hospital length of stay 
and mortality, though we included all three outcomes measures for reference.  
 
Analysis 
For descriptive statistics, mean and standard deviation (SD) or median and 
interquartile range (IQR) and range were used for continuous variables as 
appropriate. Frequencies and percentages were used for categorical variables. 
Baseline characteristics were compared across the three groups of patients using 
chi-square tests for categorical variables and F-tests (if normally distributed) or 
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Kruskal-Wallis rank test (if not normally distributed) for continuous variables. For the 
primary efficacy outcome, a one sample t-test was used to estimate the mean 
change in Hb along with its 95% confidence interval and p-value. Multiple logistic 
regression models adjusting for important baseline predictors were used for the 
secondary outcome blood transfusion. The Wilcoxon rank sum test was used to 
compare length of stay (excluding patients who had died) and for days alive and out 
of hospital. One sample t-tests were used to estimate the mean pre-post-surgery 
change in Hb and its 95% CI in each group of patients. The proportion of deaths and 
hospital readmissions were compared using a chi squared test.  
Sample size was calculated based upon change in Hb from baseline to pre-
surgery in patients who received intravenous iron. Assuming the standard deviation 
for Hb would be 12 g.L-1 based on national audit data1, we calculated that 72 patients 
would provide 90% power at a 5% significance level and 62 would provide 80% 
power (allowing for up to 10% loss to follow-up) to demonstrate a difference in the 
change from baseline in Hb of 10 g.L-1. The report was prepared according to the 






Seven of the eleven (64%) NHS hospitals successfully set up anaemia pathways or 
clinics as part of their pre-operative cardiac surgical service over the study period. 
Two centres had difficulties getting approvals for intravenous iron onto their 
pharmacy formulary; and two had the business plans refused by the hospital Trust or 
commissioners (funders).  
Two-hundred and twenty-eight patients were recruited over 2 years in 11 UK 
cardiac centres (Supplementary figure 1). The commonest reasons for failure to 
recruit patients were; administrative and lack of research staff, no date for surgery, 
date of surgical procedure outside of study treatment window (within 10 days) and 
19% of patients approached to take part refused to give consent. 
Of the 228 patients recruited before cardiac surgery; 92 (40%) patients were 
not anaemic, 72 (32%) were anaemic but not treated, and 64 (28%) were anaemic 
and received intravenous iron pre-operatively. Of the anaemic patients, who would 
ideally receive IV iron pre-treatment, only 47% (64/136) were treated, due to various 
logistical barriers. Individual TSAT/Ferritin results for all participants have not been 
included as the data were not complete at time of analysis. 
 Patients treated with intravenous iron were more likely to have a history of 
anaemia and iron deficiency and have chronic kidney disease (Table1). Those 
treated were slightly more anaemic than the non-treated group, mean (95% CI) 
difference in [Hb] -2.5 (Table 2).   
Intravenous iron was administered a median (IQR [range]) of 33 (15 - 53 [4 - 
303]) days before surgery.  Mean (SD) dose of intravenous iron was 1293 (303) mg 
with 60 patients receiving iron isomaltoside at a mean dose of 1314 (303) mg and 4 
receiving 1000mg of iron carboxymaltose. No adverse event was reported.  
 
Efficacy  
Intravenous iron was efficacious and increased average Hb in anaemic patients 
before surgery compared to those without treatment; mean (95% CI) change in Hb in 
patients treated with intravenous iron was +8.4 (5.0 to 11.8) g/L between treatment 
and surgery, p<0.001 (Table 2). Overall, transfusion rates varied from 30% to 65% 
across the study centres. Twenty-three (10%) patients received a large blood 
transfusion with greater than four units of red cells and were excluded (9 from the 
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non-anaemic group, 5 from the non-treated anaemic group and 9 from the treated 
anaemic group). Non-anaemic patients were less likely to be transfused than 
anaemic patients, 22/92 (27%) vs 59/136 (42%), adjusted OR 2.53 (1.38-4.63, 
p=0.003 (Table 3). Non-anaemic patients were also transfused fewer units of red 
cells and stayed less time in hospital and days alive at home (DAH) was higher 
(Table 3). There was no difference in transfusion rate, quantity of blood transfused or 
other outcomes between untreated anaemic patients and anaemic patients treated 
with intravenous iron (Table 4). Postoperatively, Hb was similar in all three groups. 
The greatest drop in Hb was in the non-anaemic group, 42.8 (-45.7 to -39.9) g/L, 







Although feasible, it has proven difficult to detect, diagnose and treat anaemia in 
cardiac surgical patients within the timeframe before surgery. Only a minority of 
potential patients undergoing cardiac surgery in the UK were entered into a pathway 
involving intravenous iron in a timely manner before operation. Hurdles for care were 
institutional (set up) and local (pathways). Implementation of anaemia identification 
and management in line with NICE guidance appears to have changed little in the 
last decade.20 Our study to develop and intravenous iron service preoperatively was 
in keeping with the Frankfurt PBM program results where only 57 of 1830 patients 
scheduled for surgery received intravenous iron.23 In order to set up anaemia 
detection and treatment pathways, organisational change is required and this must 
be multifactorial and cross boundaries. Expertise and buy in are essential from 
surgery, anaesthesia, haematology, pharmacy, nursing and finance departments.  
Although as a non-randomised observational study it is difficult to draw firm 
conclusions regarding efficacy, treating anaemic patients with intravenous iron 
before cardiac surgery appears to be efficacious, with a statistically and clinically 
significant increase in haemoglobin concentration, which is consistent with a meta-
analysis on the effect of intravenous iron.15 Our work also supports the findings of 
the ACTA audit data that anaemic patients are more likely to be transfused and have 
worse outcomes than non-anaemic patients.1 Whilst we did not show any effect of 
treating anaemia with intravenous iron on transfusion rate or other patient outcomes, 
this study was not powered to demonstrate such a difference and not dissimilar to 
results seen in a small pilot RCT.24  
As is often the case with observational research, the baseline characteristics 
of the study groups varied significantly. In this study population, anaemic patients 
who received intravenous iron had a significantly higher rate of pre-existing renal 
impairment. Renal impairment has a major influence on transfusion requirement as 
demonstrated in many predictive scores for transfusion risk in cardiac surgery. For 
example, if we were to calculate the risk of transfusion in a patient at intermediate 
risk of transfusion prior to cardiac using the ACTA-PORT score,25 the presence of a 
pre-operative creatinine > 177 μmol/L would shift the predicted transfusion rate from 
45% up to 60%. The higher rates of previously diagnosed anaemia (55% vs 30%), 
previous iron deficiency (39% vs 13%), and symptomatic angina (63% vs 39%) in 
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our treatment group, compared with the non-treated anaemic patients, may have 
contributed to the outcome results.   
The complex nature of cardiac surgery and multifactorial causes for 
coagulopathy with need for significant use of blood resources26 may override the 
positive effects of intravenous iron in the preoperative setting. Successful treatment 
of anaemia before cardiac surgery is possible, but there is currently no strong 
evidence it can improve cardiac surgical outcomes. In a more general context, it 
appears that intravenous iron has the ability to significantly improve Hb concentration 
and reduce risk of transfusion.27 This has been translated into expert consensus28 
and practice guidelines.17 Trials examining preoperative cardiac surgical patients 
have been encouraging, though not definitive. One large retrospective cohort trial 
showed an improvement in mortality, transfusion rate, renal failure and admission 
length29 and a smaller RCT suggested that an increase in [Hb] and a reduction in 
transfusion rates is possible.30 However, another small RCT failed to demonstrate 
that IV iron can improve [Hb],31 making the evidence rather inconclusive and 
inadequate to firmly validate the wide spread use of IV iron in this population. To 
date, this study is the largest of its kind that demonstrates intravenous iron is 
effective in treating anaemic cardiac surgical patients, within the time constraints of 
the pre-operative period. CAVIAR-UK was not designed to be the definitive study of 
the effect of intravenous iron on improving clinical outcomes in this patient group, but 
rather designed to provide information to guide design and implementation of a 
subsequent randomised controlled trial, which is now underway. 
These results suggest that further research is both possible and necessary to 
demonstrate that by effectively treating anaemia pre-operatively, we may be able to 
reverse, or improve some of the associated adverse outcomes. The study also 
demonstrates that, in the UK centres studied, there were significant deficits in 
infrastructure and process to allow timely diagnosis and treatment to achieve a 
meaningful clinical result in an appropriate timeframe. CAVIAR was designed to treat 
patients at least 10 day pre-operatively as it appears that 7-9 days is required for IV 
iron to have it peak effect on ferritin levels32 and it appears that [Hb] increase begins 
to plateau between 5-14 days.33 A recent RCT showed that giving IV Iron and EPO 
immediately before surgery showed a reduction in transfusion, but no demonstrable 
patient benefit.34 Greater access to anaemia treatment centres, such as 
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multidisciplinary pre-operative anaemia clinics, should facilitate prompt and effective 
treatment for those patients identified at risk.  
By nature of its design, this study had significant limitations. As an 
observational study, the likelihood of significant differences in baseline data is high, 
and the presence of bias and confounders is common. There were significant 
differences in baseline characteristics between the groups that could plausibly lead 
to changes in the treatment effect and measured outcomes. The study was designed 
to detect an increase in Hb concentration and therefore underpowered to detect 
outcome changes. Many of our investigators are now involved in the ITACS trial 
(NCT02632760), a larger RCT that is currently underway, which aims to demonstrate 
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Age; years 67.0 (9.7) 69.3 (11.8) 70.2 (10.9) 0.158 
Sex; men 66 (72%) 55 (76%) 46 (72%) 0.767 
Weight; kg 85.8 (17.9) 83.2 (18.0) 81.6 (17.9) 0.120 
Height; cm 170.0 
(10.0) 
168.9 (10.6) 167.6 (8.9) 0.340 









Cardiac function  
   Good 66 (73%) 55 (76%) 48 (75%)  
   Moderate 24 (26%) 15 (21%) 15 (23%)  
   Poor 1 (1%) 2 (3%) 1 (2%) 0.866 
NYHA  
   1 28 (31%) 23 (32%) 12 (19%)  
   2 43 (47%) 26 (37%) 32 (50%)  
   3 20 (22%) 17 (24%) 19 (30%)  
   4 0 5 (7%) 1 (2%) 0.042 







Medical history  
   Iron deficiency 4 (4%) 9 (13%) 25 (39%) <0.001 
   Anaemia 10 (11%) 21 (29%) 35 (55%) <0.001 
Operation  
   CABG 44 (48%) 29 (40%) 24 (38%)  
   Single Valve 29 (32%) 33 (46%) 22 (34%)  
   CABG+Valve 12 (13%) 4 (6%) 9 (14%)  
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Table 2: Haemoglobin concentration by group and time 




 n=92 n=72 n=64 
    
Mean (SD) Hb; g/L    
   Pre-treatment NA NA 114.2 (9.3) 
   Pre-surgery 141.1 (10.4) 116.7 (10.2) 122.7 (13.3) 
   Postoperative 98.3 (13.6) 93.2 (10.5) 93.7 (11.9) 
    
Mean (95% CI) change in 
Hb-g/L 
   
   Pre/post treatment NA NA 8.4 (5.0, 11.8) 
   Pre/post surgery -42.8 (-45.7 to -
39.9) 
-23.4 (-26.5 to -
20.3) 
-29.0 (-32.4 to -
25.6) 






Table 3 Study outcomes, anaemic versus non-anaemic patients, excluding 23 
patients who were transfused > 4 units red cells. Adj OR: odds ratio for blood 










Number (%) transfused 22 (26.5)  59 (48.8) 0.001 
Adj OR (95% CI)    3.18 (1.60-
6.31) 
0.001 
       
Units transfused; n(%)       
   1-2 15 (16%)  43 (32%)  
   3-4 7 (8%)  16 (12%) 0.016 
       
   Median (IQR) 0 (0-1)  1 (0-2) 0.005 
       
Died, n (%) 3 (3.3)  5 (3.7) 0.867 
       
Readmissions; n(%) 15 (16.3)  16 (11.8) 0.327 
       
ITU length of stay-days       
   Median (IQR) 2 (1-4)  2 (1-5) 0.571 
       
Hospital stay; days       
   Median (IQR) 8 (6-11)  9 (7-14.5) 0.014 
       
DAOH-30; days       






















Table 4: Study outcomes, anaemic non-treated versus anaemic treated after 
exclusion of 14 patients transfused > 4 units of blood. Adj OR, odds ratio 
adjusted for baseline haemoglobin, sex, BMI, diabetes, iron tablets, 











       
Number (%) 
transfused 
28 (42%)  31 (56%) 0.127 
Adj OR (95% 
CI) 
   1.33 (0.52-
3.40) 
0.553 
       
Units transfused; 
n(%) 
      
   1-2 18 (25.4)  25 (39.1)  
   3-4 10 (14.1)  6 (9.4) 0.107 
       
   Median (IQR) 0 (0-2)  1 (0-2) 0.082 
       
Died; n(%) 3 (4%)  2 (3%) 0.747 
       
Readmissions; n(%) 5 (7%)  11 (17%) 0.064 
       
ITU length of stay; 
days 
      
   Median (IQR) 2 (1-4)  3 (1-5) 0.158 
       
Hospital stay; days       
   Median (IQR) 9 (7-14)  10.5 (7-15) 0.492 
       
DAOH-30; days       












 Anaemic non-treated 
n=72 
 Anaemic treated 
n=64 
 Blackpool 5 (5%)  5 (7%)  0  
 Cardiff 19 (21%)  4 (6%)  21 (33%) 
 Castle Hill 13 (14%)  10 (14%)  4 (6%) 
 Derriford 13 (14%)  2 (3%)  2 (3%) 
 Essex 3 (3%)  18 (25%)  0  
 James Cook 0   2 (3%)  14 (22%) 
 Kings College 0   1 (1%)  2 (3%) 
 Liverpool 18 (20%)  12 (17%)  12 (19%) 
 Manchester RI 0   1 (1%)  0  
 Papworth 10 (11%)  5 (7%)  9 (14%) 
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Supplement Figure 1 
 
Duration of screening period for 11 cardiac units in the UK during the time course of 










































Appendix 1: CAVIAR Investigators by site 
 
Royal Free Hospital: Daniel Martin 
Papworth Hospital: Andrew Klein(PI) & James Yeates 
Cardiff (University Hospital of Wales): Caroline Evans  
Liverpool Hospital: Seema Agarwal  
Freeman Hospital: Michael Clarke 
Royal Infirmary of Edinburgh: Peter Alston 
Castle Hill Hospital: Ajith Vijayan  
Manchester Royal Infirmary: Akbar Vohra  
Essex Cardiothoracic Centre: Anirudda Pai 
Brighton & Sussex University Hospitals: Anita Sugavanam 
Guy’s & St. Thomas Hospital: Jugdeep Dhesi 
Royal Oldham Hospital: Damian Kelleher 
Royal Cornwall Hospital: Harvey Chant 
Royal Blackpool Hospital: Palanikumar Saravanan 
Royal Bournemouth Hospital: Richard Green 
University Hospitals of Leicester: Matthew Bown  
Derriford Hospital: Mark Bennett  
King’s College Hospital: Gudrun Kunst 
James Cook University Hospital: Adrian Mellor 
